Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Axsome Therapeutics, Inc. related to misrepresentation of the company's practices and prospects [1] Group 1: Allegations of Misrepresentation - Insiders at Axsome allegedly caused the company to misrepresent or fail to disclose deficiencies in its chemistry, manufacturing, and control (CMC) practices concerning AXS-07 [2] - As a result of these deficiencies, Axsome was unlikely to submit the AXS-07 New Drug Application (NDA) on the initially represented timeline [2] - The unresolved CMC issues were present during the FDA's review of the AXS-07 NDA, leading to a low likelihood of FDA approval [2] - Consequently, Axsome overstated AXS-07's regulatory and commercial prospects, making the company's public statements materially false and misleading [2]